DALLAS--(BUSINESS WIRE)--HemoBioTech (OTCBB:HMBT) (www.hemobiotech.com) announced today that Dr. Arthur P. Bollon, Chairman & CEO, will present the development strategy for its blood substitute, HemoTech, at the RENN Capital Investor Conference on May 15, 2009. Dr. Bollon will discuss the global need for a safe blood substitute as an alternative to contaminated blood. About 10% of new HIV/AIDS cases are due to HIV contaminated blood globally. RENN Capital is the leading institutional investor in HemoBioTech.
